<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">oncotomsk</journal-id><journal-title-group><journal-title xml:lang="ru">Сибирский онкологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Siberian journal of oncology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1814-4861</issn><issn pub-type="epub">2312-3168</issn><publisher><publisher-name>Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21294/1814-4861-2018-17-5-21-26</article-id><article-id custom-type="elpub" pub-id-type="custom">oncotomsk-854</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL STUDIES</subject></subj-group></article-categories><title-group><article-title>ОПТИМИЗАЦИЯ ПЕРВИЧНОЙ ТРАНСРЕКТАЛЬНОЙ МУЛЬТИФОКАЛЬНОЙ БИОПСИИ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ ПО ДАННЫМ ПЕРФУЗИОННОЙ КОМПЬЮТЕРНОЙ ТОМОГРАФИИ</article-title><trans-title-group xml:lang="en"><trans-title>OPTIMIZATION OF PRIMARY TRANSRECTAL MULTIFOCAL PROSTATE BIOPSY USING PERFUSION COMPUTED TOMOGRAPHY</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сосновский</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Sosnovskiy</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сосновский Никита Валерьевич, врач-уролог</p><p>194354, г. Санкт-Петербург, ул. Сикейроса, 10/А</p></bio><bio xml:lang="en"><p>Nikita V. Sosnovsky, MD, physician</p><p>10/A, Siqueiros Street, St. Petersburg-194354</p></bio><email xlink:type="simple">rologsosnovskiy@yanndex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Школьник</surname><given-names>М. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Shkolnik</surname><given-names>М. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Школьник Михаил Иосифович, доктор медицинских наук, руководитель отделения оперативной онкологии и оперативной урологии</p><p>197758, г. Санкт-Петербург, пос. Песочный, ул. Ленинградская, 70</p><p>SPIN-код: 4743-9236. AuthorID (РИНЦ): 92957</p></bio><bio xml:lang="en"><p>Mikhail I. Shkolnik, MD, DSc, Head of Surgical Oncology and Urology</p><p>70, Leningradskaya Str., St.-Petersburg, Pesochny-197758</p></bio><email xlink:type="simple">Shkolnik_phd@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Розенгауз</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Rozengauz</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Розенгауз Евгений Владимирович, доктор медицинских наук, руководитель отделения рентгеновской компьютерной томографии, ФГБУ «Российский научный центр радиологии и хирургических технологий им. академика А.М. Гранова»; профессор кафедры лучевой диагностики и лучевой терапии, ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова»</p><p>197758, г. Санкт-Петербург, пос. Песочный, ул. Ленинградская, 70, 191015, г. Санкт-Петербург, ул. Кирочная, 41</p><p>SPIN-код: 5662-6639. AuthorID (РИНЦ): 568607</p></bio><bio xml:lang="en"><p>Evgeny V. Rozengauz, MD, DSc, Head of Computed Tomography Department, Russian Scientific Center of Radiology and Surgical Technologies named after A.M. Granov; Professor of Diagnostic Imaging and Radiation Therapy Department, North-Western State Medical University named after I.I. Mechnikov</p><p>70, Leningradskaya Str., St.-Petersburg, Pesochny-197758,</p><p>41, Kirochnaya Street, St. Petersburg-191015</p></bio><email xlink:type="simple">rozengaouz@yandex.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Нестеров</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Nesterov</surname><given-names>D. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Нестеров Денис Валерьевич, кандидат медицинских наук, ассистент кафедры лучевой диагностики и лучевой терапии</p><p>191015, г. Санкт-Петербург, ул. Кирочная, 41</p><p>SPIN-код: 1402-7132. AuthorID (РИНЦ): 928290</p></bio><bio xml:lang="en"><p>Denis V. Nesterov, MD, PhD, Imaging and Radiation Therapy Department</p><p>41, Kirochnaya Street, St. Petersburg-191015</p></bio><email xlink:type="simple">cireto@gmail.com</email><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>СПб ГБУЗ «Городская поликлиника № 104»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Municipal Polyclinic № 104</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ «Российский научный центр радиологии и хирургических технологий им. академика А.М. Гранова»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Russian Scientific Center for Radiology and Surgical Technologies named after Academician A.M. Granov</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБУ «Российский научный центр радиологии и хирургических технологий им. академика А.М. Гранова»;&#13;
ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Russian Scientific Center for Radiology and Surgical Technologies named after Academician A.M. Granov;&#13;
North-Western State Medical University named after I.I. Mechnikov</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>North-Western State Medical University named after I.I. Mechnikov</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>31</day><month>10</month><year>2018</year></pub-date><volume>17</volume><issue>5</issue><fpage>21</fpage><lpage>26</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Сосновский Н.В., Школьник М.И., Розенгауз Е.В., Нестеров Д.В., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Сосновский Н.В., Школьник М.И., Розенгауз Е.В., Нестеров Д.В.</copyright-holder><copyright-holder xml:lang="en">Sosnovskiy N.V., Shkolnik М.I., Rozengauz E.V., Nesterov D.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.siboncoj.ru/jour/article/view/854">https://www.siboncoj.ru/jour/article/view/854</self-uri><abstract><sec><title>Введение</title><p>Введение. Стандартным методом верификации рака предстательной железы (РПЖ) является первичная трансректальная мультифокальная биопсия предстательной железы (ПЖ) под ультразвуковым (УЗ) контролем. Частота выявления РПЖ при данном подходе достигает 53 %.</p><p>Цель исследования – улучшение результатов первичной трансректальной мультифокальной биопсии предстательной железы под ультразвуковым контролем с помощью её оптимизации за счёт перфузионной компьютерной томографии (ПКТ).</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В исследование было включено 97 пациентов с показаниями к выполнению первичной биопсии ПЖ. Всем больным перед биопсией выполнялась ПКТ ПЖ. В результате обследования у 54 пациентов не было выявлено очаговых изменений по данным ПКТ, у 43 выявлены. Больным с выявленными по данным ПКТ очаговыми изменениями выполнялась стандартная первичная трансректальная мультифокальная биопсия предстательной железы и дополнительные вколы из подозрительного участка по данным ПКТ. Сопоставлялась информативность стандартных и прицельных вколов по данным ПКТ в группе пациентов с выявленными очаговыми изменениями. Статистическую значимость различий оценивали с помощью критерия Мак-Немара.</p></sec><sec><title>Результаты</title><p>Результаты. Статистически значимых различий в частоте выявления рака предстательной железы при применении стандартных и прицельных вколов выявлено не было (p&gt;0,05). Однако статистически значимые различия в выявлении РПЖ разной степени дифференцировки были обнаружены между стандартными и прицельными вколами для РПЖ с суммой Глисона 8 (4 + 4). Выявляемость РПЖ с суммой Глисона 8 (4 + 4) для стандартных вколов составила 5 %, для прицельных – 14 % (p˂0,05). Ни один статистический метод не был использован для оценки чувствительности и специфичности ввиду отсутствия «золотого» стандарта (гистологического исследования всего объёма ткани ПЖ после радикальной простатэктомии) у всех пациентов, вошедших в группу.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. Primary transrectal multifocal prostate biopsy is the standard method for prostate cancer (PCa) verification, with the detection rate of 53 %. The purpose of the study was to improve findings of transrectal ultrasound-guided prostate biopsy (TRUS-biopsy) by its optimization due to perfusion computed tomography (PCT).</p></sec><sec><title>Material and methods</title><p>Material and methods. The study included 97 patients with indications for TRUS-biopsy. All patients underwent PCT of the prostate before biopsy. Prostate cancer was detected by PCT in 43 patients. These patients underwent standard primary transrectal multifocal prostate biopsy plus additional targeted punctures from areas of increased blood flow. The results of standard and targeted punctures were compared. The McNemar criterion was used to assess the statistical significance of the differences.</p></sec><sec><title>Results</title><p>Results. There were no statistically significant differences in the incidence of PCa detection between standard and targeted punctures (p&gt;0.05). However, statistically significant differences in the detection of PCa of different differentiation grades were found between standard and targeted punctures for PCa with a Gleason score of 8 (4 + 4). The detection rate of PCa with the Gleason score of 8 (4 + 4) was 5 % for standard punctures and 14 % for targeted punctures (p˂0.05). No one statistical method has been used to assess sensitivity and specificity, due to the absence of a «gold» standard (histological examination of the total amount of prostate tissue after radical prostatectomy).</p></sec><sec><title>Conclusion</title><p>Conclusion. The use of primary prostate biopsy optimized with PCT findings does not allow increase in the detection rate of PCa. However, this method improves the verification of PCa with a Gleason score of 8 (4 + 4) that can influence the risk stratification and selection of further therapeutic strategy.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>рак предстательной железы</kwd><kwd>первичная биопсия предстательной железы</kwd><kwd>перфузионная компьютерная томография</kwd><kwd>индекс Глисона</kwd></kwd-group><kwd-group xml:lang="en"><kwd>prostate cancer</kwd><kwd>perfusion computed tomography</kwd><kwd>Gleason score</kwd><kwd>flow rate</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). М., 2017. 250.</mixed-citation><mixed-citation xml:lang="en">Kaprin A.D., Starinsky V.V., Petrova G.V. Cancer incidence and mortality in Russia in 2015. Moscow, 2017. 250. (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Алексеев Б.Я., Каприн А.Д., Матвеев В.Б., Нюшко К.М. Клини‑ ческие рекомендации по диагностике и лечению рака предстательной железы. М., 2014. 43.</mixed-citation><mixed-citation xml:lang="en">Alekseev B.Ya., Kaprin A.D., Matveev V.B., Nyushko K.M. Guidelines for diagnosis and treatment of prostate cancer. Moscow, 2014. 43. (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Сосновский Н.В., Розенгауз Е.В., Школьник М.И., Нестеров Д.В., Арзуманов А.А. Использование 320-срезовой перфузионной ком‑ пьютерной томографии в визуализации рака предстательной железы. Ученые записки СПбГМУ им. акад. И.П. Павлова. 2016; 23 (4): 76–80.</mixed-citation><mixed-citation xml:lang="en">Sosnowski N.V., Rozengauz E.V., Shkolnik M.I., Nesterov D.V., Arzumanov A.A. Use of 320-section perfusion computed tomography in visualization of prostate cancer. The Scientific Notes of the I.P. Pavlov St. Petersburg State Medical University. 2016; 23 (4): 76–80. (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Pelzer A., Bektic J., Berger A.P., Pallwein L., Halpern E.J., Horninger W., Bartsch G., Frauscher F. Prostate cancer detection in men with prostate specific antigen 4 to 10 ng/ml using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy. J Urol. 2005; 173 (6): 1926–9. doi: 10.1097/01.ju.0000158444.56199.03.</mixed-citation><mixed-citation xml:lang="en">Pelzer A., Bektic J., Berger A.P., Pallwein L., Halpern E.J., Horninger W., Bartsch G., Frauscher F. Prostate cancer detection in men with prostate specific antigen 4 to 10 ng/ml using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy. J Urol. 2005; 173 (6): 1926–9. doi: 10.1097/01.ju.0000158444.56199.03.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Eichler K., Hempel S., Wilby J., Myers L., Bachmann L.M., Kleijnen J. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol. 2006; 175 (5): 1605–12. doi: 10.1016/S0022-5347(05)00957-2</mixed-citation><mixed-citation xml:lang="en">Eichler K., Hempel S., Wilby J., Myers L., Bachmann L.M., Kleijnen J. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol. 2006; 175 (5): 1605–12. doi: 10.1016/S0022-5347(05)00957-2</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Bjurlin M., Rosenkrantz A., Taneja S. Role of MRI prebiopsy in men at risk for prostate cancer: taking off the blindfold. Curr Opin Urol. 2017 May; 27 (3): 246–253. doi: 10.1097/MOU.0000000000000389.</mixed-citation><mixed-citation xml:lang="en">Bjurlin M., Rosenkrantz A., Taneja S. Role of MRI prebiopsy in men at risk for prostate cancer: taking off the blindfold. Curr Opin Urol. 2017 May; 27 (3): 246–253. doi: 10.1097/MOU.0000000000000389.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Pokorny M., Van de Ven W., Barentsz J., Thompson L. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol. 2015 Mar; 67 (3): e54–5. doi: 10.1016/j.eururo.2014.08.066.</mixed-citation><mixed-citation xml:lang="en">Pokorny M., Van de Ven W., Barentsz J., Thompson L. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol. 2015 Mar; 67 (3): e54–5. doi: 10.1016/j.eururo.2014.08.066.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Tonttila P.P., Lantto J., Pääkkö E., Piippo U., Kauppila S., Lammentausta E., Ohtonen P., Vaarala M.H. Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsynaive Men with Suspected Prostate Cancer Based on Elevated Prostatespecific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial. Eur Urol. 2016 Mar; 69 (3): 419–25. doi: 10.1016/j.eururo.2015.05.024.</mixed-citation><mixed-citation xml:lang="en">Tonttila P.P., Lantto J., Pääkkö E., Piippo U., Kauppila S., Lammentausta E., Ohtonen P., Vaarala M.H. Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsynaive Men with Suspected Prostate Cancer Based on Elevated Prostatespecific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial. Eur Urol. 2016 Mar; 69 (3): 419–25. doi: 10.1016/j.eururo.2015.05.024.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Winther M.D., Balslev I., Boesen L., Logager V., Noergaard N., Thestrup K.D., Thomsen H.S. Magnetic resonance imaging-guided biopsies may improve diagnosis in biopsy-naive men with suspicion of prostate cancer. Dan Med J. 2017 May; 64 (5). pii: A5355.</mixed-citation><mixed-citation xml:lang="en">Winther M.D., Balslev I., Boesen L., Logager V., Noergaard N., Thestrup K.D., Thomsen H.S. Magnetic resonance imaging-guided biopsies may improve diagnosis in biopsy-naive men with suspicion of prostate cancer. Dan Med J. 2017 May; 64 (5). pii: A5355.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Prando A., Wallace S. Helical CT of prostate cancer: early clinical experience. AJR Am J Roentgenol. 2000 Aug; 175 (2): 343–6.</mixed-citation><mixed-citation xml:lang="en">Prando A., Wallace S. Helical CT of prostate cancer: early clinical experience. AJR Am J Roentgenol. 2000 Aug; 175 (2): 343–6.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ives E.P., Burke M.A., Edmonds P.R., Gomella L.G., Halpern E.J. Perfusion of Prostate Cancer: Correlation with Whole-Mount Pathology. Clin Prostate Cancer. 2005 Sep; 4 (2): 109–12.</mixed-citation><mixed-citation xml:lang="en">Ives E.P., Burke M.A., Edmonds P.R., Gomella L.G., Halpern E.J. Perfusion of Prostate Cancer: Correlation with Whole-Mount Pathology. Clin Prostate Cancer. 2005 Sep; 4 (2): 109–12.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Osimani M., Bellini D., Di Cristofano C., Palleschi G., Petrozza V., Carbone A., Laghi A. Perfusion MDCT of Prostate Cancer: Correlation of Perfusion CT Parameters and Immunohistochemical Markers of Angiogenesis. AJR Am J Roentgenol. 2012 Nov; 199 (5): 1042–8. doi: 10.2214/AJR.11.8267.</mixed-citation><mixed-citation xml:lang="en">Osimani M., Bellini D., Di Cristofano C., Palleschi G., Petrozza V., Carbone A., Laghi A. Perfusion MDCT of Prostate Cancer: Correlation of Perfusion CT Parameters and Immunohistochemical Markers of Angiogenesis. AJR Am J Roentgenol. 2012 Nov; 199 (5): 1042–8. doi: 10.2214/AJR.11.8267.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Łuczyńska E., Heinze-Paluchowska S., Blecharz P., JereczekFossa B., Petralia G., Bellomi M., Stelmach A. Correlation between CT Perfusion and Clinico-Pathological Features in Prostate Cancer: A Prospective Study. Med Sci Monit. 2015 Jan 13; 21: 153–62. doi: 10.12659/MSM.891401.</mixed-citation><mixed-citation xml:lang="en">Łuczyńska E., Heinze-Paluchowska S., Blecharz P., JereczekFossa B., Petralia G., Bellomi M., Stelmach A. Correlation between CT Perfusion and Clinico-Pathological Features in Prostate Cancer: A Prospective Study. Med Sci Monit. 2015 Jan 13; 21: 153–62. doi: 10.12659/MSM.891401.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ferrari M., Huellner M., Pauli C., Seifert B., Danuser H., VeitHaibach P., Mattei A. Assessment of prostate cancer with integrated CTperfusion using a sector-wise approach. Turk J Urol. 2017 Jun; 43 (2): 152–157. doi: 10.5152/tud.2017.11455.</mixed-citation><mixed-citation xml:lang="en">Ferrari M., Huellner M., Pauli C., Seifert B., Danuser H., VeitHaibach P., Mattei A. Assessment of prostate cancer with integrated CTperfusion using a sector-wise approach. Turk J Urol. 2017 Jun; 43 (2): 152–157. doi: 10.5152/tud.2017.11455.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Weinreb J.C., Barentsz J.O., Choyke P.L., Cornud F., Haider M.A., Macura K.J., Thoeny H.C. PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2. European Urology. 2016; 69 (1): 16–40.</mixed-citation><mixed-citation xml:lang="en">Weinreb J.C., Barentsz J.O., Choyke P.L., Cornud F., Haider M.A., Macura K.J., Thoeny H.C. PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2. European Urology. 2016; 69 (1): 16–40.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Humphrey P.A. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol. 2004 Mar; 17 (3): 292–306.</mixed-citation><mixed-citation xml:lang="en">Humphrey P.A. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol. 2004 Mar; 17 (3): 292–306.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
